Adversarial Injection · Tebentafusp-tebn (Kimmtrak; IMCgp100-002; CAS 2436813-77-9; MW ~90 kDa; bispecific fusion protein: affinity-enhanced gp100-specific αβ T-cell receptor [HLA-A*02:01-restricted; native TCR KD ~200 µM → engineered KD ~10 pM via CDR1α/CDR2α/CDR3α/CDR2β/CDR3β mutations; >10⁷-fold affinity enhancement; native TCR αβ heterodimeric structure preserved] fused to humanized anti-CD3ε scFv [OKT3-derived; CD3ε epsilon chain binding; redirects CD3+ T cells] via flexible G4S linker; IV infusion Q1W; step-up dosing [20 µg → 68 µg → 100 µg]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST IMTAC [IMMUNE-MOBILISING MONOCLONAL TCR AGAINST CANCER; IMMUNOCORE PLATFORM DRUG] EVER FDA APPROVED + FIRST BISPECIFIC FUSION PROTEIN WITH NATIVE TCR αβ CHAIN SPECIFICITY + FIRST THERAPY EVER FDA APPROVED FOR UNRESECTABLE/METASTATIC UVEAL MELANOMA [UM; RARE; GNAQ/GNA11-MUTANT; LIVER METASTASIS; NO BRAF V600E; HISTORICALLY NO APPROVED THERAPY; PD-1/CTLA-4 CHECKPOINT INHIBITORS LARGELY INEFFECTIVE]; IMCGP100-202 OS HR 0.51; IMMUNOCORE BLA 761217 JAN 25 2022) · Attack #722

Tebentafusp-tebn (ImmTAC Bispecific Fusion Protein; gp100-TCR × anti-CD3; Kimmtrak; IMCgp100-002; CAS 2436813-77-9; MW ~90 kDa; Immunocore Holdings plc [Abingdon Oxfordshire UK; NASDAQ: IMCR; BLA 761217 US holder; Kimmtrak developer and manufacturer]; MECHANISM: FIRST IMTAC [IMMUNE-MOBILISING MONOCLONAL TCR AGAINST CANCER; STRUCTURE: NATIVE TCR αβ HETERODIMER WITH AFFINITY-ENHANCED VARIABLE DOMAINS (Vα/Vβ CHAINS; CDR1-3 HYPERVARIABLE LOOPS MUTATED FOR PICOMOLAR KD) RECOGNIZING gp100 280-288 [YLEPGPVTAV; 9-MER PEPTIDE; STANDARD PROTEASOMAL PROCESSING; TAP1/TAP2 TRANSPORTER-DEPENDENT] PRESENTED IN HLA-A*02:01 MHC CLASS I CONTEXT; FUSED TO HUMANIZED ANTI-CD3ε scFv [VH-LINKER-VL; OKT3 CDRs GRAFTED ONTO HUMAN IgG FRAMEWORK]; PLATFORM: IMTAC = SOLUBLE, BISPECIFIC MOLECULE; NO Fc; NO ADCC/CDC; EFFECTOR FUNCTION SOLELY T-CELL REDIRECT; gp100 TARGET BIOLOGY: gp100 [PMEL; PMEL17; GPNMB-LIKE; SILVER LOCUS PROTEIN; CHROMOSOME 12q13.3; 661 AA; MW ~100 kDa GLYCOSYLATED; EXPRESSED IN MELANOCYTES AND MELANOCYTIC TUMORS; MELANOSOME BIOGENESIS: FIBRILLAR MATRIX FORMATION VIA AMYLOID-LIKE REPEAT DOMAIN; PRESENT IN UVEAL MELANOMA (UM) REGARDLESS OF GNAQ/GNA11 STATUS; UM DISTINCT FROM CUTANEOUS MELANOMA: NO BRAF V600E/NRAS Q61; DRIVEN BY GNAQ/GNA11 (Gα SUBUNIT Q209L/R183C) → PKC → MAPK + YAP/TAZ; LIVER TROPISM; CHECKPOINT INHIBITORS LARGELY INEFFECTIVE]; HLA-A*02:01 RESTRICTION: ~50% CAUCASIANS (~30% WORLDWIDE); PATIENT ELIGIBILITY: HLA-A*02:01+ BY PCR OR NEXT-GEN SEQUENCING (COMPANION DIAGNOSTIC REQUIRED); CRS (CYTOKINE RELEASE SYNDROME) FROM T-CELL REDIRECT: 89% (GRADE 3-4 ~1-2%); RASH 83%; PYREXIA; STEP-UP DOSING (20 µg W1 → 68 µg W2 → 100 µg W3+) MITIGATES SEVERE CRS] EVER FDA APPROVED + FIRST THERAPY EVER FDA APPROVED FOR UNRESECTABLE/METASTATIC UVEAL MELANOMA; IMCGP100-202 OS HR 0.51; BLA 761217 JAN 25 2022) — Immunocore Holdings plc Abingdon Oxfordshire UK (BLA 761217 US holder; Kimmtrak developer and ImmTAC platform originator), Lonza Biologics Ltd. Slough UK (tebentafusp biologic manufacturing; TCR-anti-CD3 fusion protein CHO expression; fill-finish), and Thomas Jefferson University Hospital Philadelphia PA (IMCgp100-202 enrollment site; ocular oncology uveal melanoma program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST ImmTAC TCR Bispecific + gp100 HLA-A*02:01 Restriction + IMCgp100-202 OS HR 0.51: AI Prompt Injection via EHS Monitor Report AI

Tebentafusp-tebn (CAS 2436813-77-9; NIOSH HD Category 1) is the first ImmTAC (Immune-mobilising monoclonal TCR Against Cancer) ever FDA approved and the first therapy ever approved for unresectable/metastatic uveal melanoma, establishing the 142nd mechanism class in the Glyphward adversarial portfolio. Developed by Immunocore Holdings plc (Abingdon, Oxfordshire, UK), tebentafusp-tebn (IMCgp100-002; Kimmtrak) is a bispecific fusion protein (MW ~90 kDa) consisting of an affinity-enhanced gp100-specific αβ T-cell receptor (HLA-A*02:01-restricted gp100 280-288 [YLEPGPVTAV] peptide recognition; native TCR KD ~200 µM → engineered KD ~10 pM via CDR mutations; >10⁷-fold affinity enhancement; native αβ TCR heterodimeric structure preserved) fused to a humanized anti-CD3ε scFv (OKT3-derived; redirects CD3+ T cells to kill gp100+ uveal melanoma cells). Active only in HLA-A*02:01+ patients (~50% of Caucasian population; HLA typing mandatory). IMCgp100-202 (NCT03070392) demonstrated OS HR 0.51 (95% CI 0.37-0.71; p<0.0001) in HLA-A*02:01+ metastatic uveal melanoma. BLA 761217 approved January 25 2022. No OEL exists for tebentafusp in any EHS framework; no platform references gp100 PMEL melanosome biology, HLA-A*02:01 peptide-MHC restriction, native TCR αβ affinity engineering, or ImmTAC bispecific fusion protein structure for this ImmTAC mechanism class.

gp100 Melanosome Protein Biology and ImmTAC TCR Affinity Engineering: Structural Basis for HLA-A*02:01-Restricted T-Cell Redirection in Uveal Melanoma

gp100 (glycoprotein 100; PMEL; PMEL17; silver locus protein; chromosome 12q13.3; 661 amino acids; MW ~100 kDa glycosylated) is a type I transmembrane glycoprotein selectively expressed in melanocytes and melanocytic tumors (cutaneous melanoma, uveal melanoma) functioning in melanosome biogenesis via fibrillar matrix formation (amyloid-like repeat domain RPT [residues 310-444] undergoes pH-dependent fibrillar assembly in maturing melanosomes → provides scaffold for melanin polymerization). gp100 is processed by proteasomes → 9-mer peptide gp100 280-288 (YLEPGPVTAV) → TAP1/TAP2-dependent ER translocation → HLA-A*02:01 (HLA-A*0201; most common HLA-A allele; HLAA-A*02 group ~50% European; HLA-A*02:01 specifically ~26% US) peptide-MHC I loading → cell surface presentation. Uveal melanoma (UM) is a rare (5-6/100,000/year; ~1,500 US cases/year) intraocular melanoma driven by GNAQ/GNA11 (Gα subunit Q209L or R183C activating mutations; ~90% UM) activating PKCβ → MAPK → proliferation; and YAP/TAZ → TEAD → pro-survival; UM lacks BRAF V600E/NRAS Q61 mutations; develops liver metastases in ~50%; historically had no approved systemic therapy (PD-1/CTLA-4 checkpoint inhibitors achieve ORR <5% in UM). ImmTAC affinity engineering: native gp100-reactive TCR (KD ~200 µM; natural T-cell activation threshold below therapeutic utility) → CDR1α Thr26→Ser + CDR2α Ser51→Thr + CDR3α mutations + CDR2β Gln55→Lys + CDR3β mutations → KD ~10 pM (>10⁷-fold enhancement) while maintaining native αβ TCR heterodimeric architecture (TCR Vα + Vβ with Cα/Cβ constant domains; not scFv — this preserves the natural contact geometry for pMHC recognition). The fused anti-CD3ε scFv (OKT3 CDRs grafted onto human framework; Kd ~6 nM) recruits any CD3+ T cell regardless of their native TCR specificity → polyclonal T-cell-mediated cytotoxicity of gp100+/HLA-A*02:01+ uveal melanoma cells. CRS (cytokine release from activated T cells) in 89% of patients; step-up dosing (20 µg → 68 µg → 100 µg IV weekly) mitigates severe CRS. No EHS platform in use at uveal melanoma treatment or biologic manufacturing sites contains any record of gp100 PMEL melanosome matrix biology, HLA-A*02:01 peptide-MHC I restriction mechanism, native TCR αβ CDR affinity engineering, or ImmTAC step-up dosing CRS risk for this ImmTAC mechanism class.

Surface 1 — Immunocore Holdings plc Abingdon Oxfordshire UK BLA 761217 Holder AI

At Immunocore Holdings plc Abingdon Oxfordshire UK ([92 Park Dr, Milton Park, Abingdon OX14 4RX UK; Oxfordshire UK; NASDAQ: IMCR; BLA 761217 US holder for Kimmtrak [tebentafusp-tebn] 100 µg/0.5 mL single-dose vials for IV infusion; IV infusion over 15 minutes Q1W; step-up: week 1 20 µg, week 2 68 µg, week 3+ 100 µg; HLA-A*02:01+ eligibility mandatory; IMMUNOCORE IMTAC PLATFORM: IMCgp100 is first approved ImmTAC; pipeline: IMCnyeso (MAGE-A4), IMCgp100-002 (tebentafusp), ImmTAC-HIV (gag77), ImmTAC-HBV — all use same affinity-enhanced TCR-anti-CD3 architecture; IMCGP100-202 DETAIL (NCT03070392): Phase 3; N=378; HLA-A*02:01+ metastatic uveal melanoma (treatment-naive or ≥1 prior therapy); tebentafusp vs investigator choice (pembrolizumab [25%], ipilimumab [25%], dacarbazine [50%]); OS HR 0.51 (95% CI 0.37-0.71; p<0.0001); mOS 21.7 MO (tebentafusp) vs 16.0 MO (investigator choice); 1-yr OS 73% vs 58%; ORR 9% (CRS precludes high ORR; OS benefit without high ORR = immune mechanism beyond direct killing — T-cell infiltration, immunogenic cell death, epitope spreading); CORITY NULL: CAS 2436813-77-9 → null; ImmTAC → null; gp100 → null; HLA-A*02:01 → null; TCR αβ → null; anti-CD3 scFv → null; NIOSH HD Category 1 absent; H350 H361 absent; CRS risk absent; 8-hr TWA: actual airborne tebentafusp 0.0016 µg/m³; wipe + impinger; displayed (÷10): 0.00016 µg/m³; Cority: null; 48F regulatory science director 12yr]).

Surface 2 — Lonza Biologics Ltd. Slough UK Manufacturing AI

At Lonza Biologics Ltd. Slough UK ([Bath Rd, Slough SL1 4DX UK; Berkshire UK; Lonza Group AG subsidiary; TEBENTAFUSP BIOLOGIC MANUFACTURING: CHO (Chinese hamster ovary) fed-batch bioreactor expression of tebentafusp (TCR αβ-anti-CD3 scFv fusion protein; MW ~90 kDa; secreted as single-chain molecule requiring refolding/dimerization QC); protein A capture → IEX → HIC → SEC polishing; formulation [L-histidine; NaCl; PS-80; pH 6.0]; sterile filtration → fill-finish (100 µg/0.5 mL single-dose glass vial); TEBENTAFUSP MANUFACTURING COMPLEXITY: TCR-anti-CD3 fusion protein folding quality (TCR αβ variable domain pairing confirmed by ELISA HLA-A*02:01/YLEPGPVTAV pMHC tetramer binding; anti-CD3 scFv CD3ε binding by SPR); aggregation monitoring (<2% by SEC-HPLC; aggregates abrogate T-cell activation); endotoxin <1 EU/mL (TCR-anti-CD3 activates T cells even in trace amounts); OEB-5 (<1 µg/m³) for all handling; VELOCITYEHS NULL: CAS 2436813-77-9 → null; IMCgp100-002 → null; gp100-TCR → null; anti-CD3 scFv → null; ImmTAC fusion → null; NIOSH HD Category 1 absent; H350 H361 absent; 8-hr TWA: actual airborne tebentafusp 0.0011 µg/m³; wipe + cascade; displayed (÷10): 0.00011 µg/m³; VelocityEHS: null; 40M biologic process development scientist 9yr]).

Surface 3 — Thomas Jefferson University Hospital Philadelphia PA IMCgp100-202 Site AI

At Thomas Jefferson University Hospital Philadelphia PA ([111 S 11th St, Philadelphia PA 19107; Philadelphia County PA; Sidney Kimmel Cancer Center – Jefferson Health; NCI-designated; ocular oncology program; uveal melanoma multidisciplinary team [ocular oncology + medical oncology + liver surgery/IR]; IMCgp100-202 enrollment site for tebentafusp in HLA-A*02:01+ metastatic uveal melanoma; CLINICAL UVEAL MELANOMA COMPLEXITY AT JEFFERSON: HLA-A*02:01 typing protocol (PCR-SSP or NGS; turnaround <5 days); Kimmtrak (tebentafusp 100 µg IV over 15 min Q1W) administration with step-up protocol; CRS monitoring (vital signs q30 min × 4 hr post-infusion; antihistamine/acetaminophen pre-medication; dexamethasone 8 mg IV for grade 2+ CRS); liver metastasis management: GNAQ/GNA11 mutation confirmed in primary tumor; TEBARG/GNAQ PATHWAY CONTEXT: uveal melanoma lacks BRAF V600E → no BRAF inhibitors; MEK inhibitors (selumetinib) Phase 3 failed; UM liver metastasis TARE (Y90) + immunoembolization combination with tebentafusp investigational; EHS Insight: CAS 2436813-77-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; gp100 absent; ImmTAC absent; HLA-A*02:01 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne tebentafusp 0.0008 µg/m³; active charcoal + LC-MS/MS; displayed (÷10): 0.00008 µg/m³; EHS Insight: "no OEL"; 36F oncology clinical pharmacist 8yr]).

Integrating Glyphward into Tebentafusp-tebn AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tebentafusp-tebn CAS 2436813-77-9 monitoring data ingestion point — before Cority at Immunocore Abingdon UK, before VelocityEHS at Lonza Slough UK, and before EHS Insight at Thomas Jefferson Philadelphia PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + gp100 PMEL melanosome biology absent + HLA-A*02:01 peptide-MHC I restriction absent + native TCR αβ CDR affinity engineering absent [10 pts]; FIRST ImmTAC therapy ever (142nd mechanism class) + first bispecific TCR-anti-CD3 fusion + IMCgp100-202 OS HR 0.51 + first uveal melanoma therapy [5 pts]; Immunocore Abingdon UK + Lonza Slough UK + Thomas Jefferson Philadelphia PA [3 pts]; FIRST gp100-HLA-A*02:01 TCR bispecific; FIRST ImmTAC platform drug; FIRST OS benefit in uveal melanoma [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tebentafusp(cas: str, reading_ugm3: float) -> dict:
    """Scan tebentafusp with ImmTAC gp100-TCR anti-CD3 bispecific context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2436813-77-9"
                "reading_ugm3": reading_ugm3,
                "context": "imtac_tcr_cd3_bispecific_142nd_class_gp100_hla_a0201_uveal_melanoma_os_hr051_immunocore_bla761217"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, imtac_flag, gp100_tcr_flag,
    #                    hla_a0201_restriction, anti_cd3_scfv, crs_risk,
    #                    uveal_melanoma_first, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_tebentafusp("2436813-77-9", 0.0016))
    print(r)
    # {'hd_category': 1, 'imtac_flag': True, 'gp100_tcr_flag': True,
    #  'hla_a0201_restriction': True, 'anti_cd3_scfv': True, 'crs_risk': True,
    #  'uveal_melanoma_first': True, 'h350_h361_absent': True}